pro-ACTINA SA is a research-driven and innovation-focused clinical stage SME, founded in 2006 in Athens-Greece. Pro-ACTINA started its operation as a Contract Research Organisation, offering chemistry services to pharma and biotech companies worldwide. During the past years, through the establishment of collaborations with the academia, industry and other SMEs, the company's activities have been shifted to the diagnostics/ biomarker field and the "SME Instrument" grant awarded in 2015 gave the boost towards this direction. Pro-ACTINA's vision is to become a leader in the diagnostics for brain abnormalities by building in-house expertise and by establishing strategic collaborations for the development of novel non-invasive diagnostic tools. Our mission is to provide patients and doctors with innovative, cost-effective diagnostic solutions as integrated parts of precision-medicine approaches. pro-ACTINA is currently partnering with both academia and industry for the implementation of GLIOMARK, a “Horizon 2020” 4-year project for the clinical validation of an in vivo biomarker for brain tumour (glioma) diagnosis. The end product will consist of a diagnostic radiopharmaceutical kit, containing tetrofosmin, for Single-Photon Emission Computed Tomography (SPECT), repositioned (by both clinical & pharmaceutical development) specifically for brain imaging. This non-invasive diagnostic technique will provide reliable glioma diagnosis with high sensitivity & specificity aiming to reduce the need for invasive and costly biopsy. Orphan drug designation has been granted by EMA for tetrofosmin for the diagnosis of glioma, thus ensuring 10 years of market exclusivity. The end-product is expected to be ready for Marketing Authorisation Application to EMA by 2021. For more information see: www.gliomark.eu